Citation: | OU Yanglong, XIAO Yaxiong. In vitro antibacterial roles of carbapenem-resistant Acinetobacter baumannii by tannic acid and different cefoperazone sodium-to-sulbactam sodium ratios[J]. Journal of Clinical Medicine in Practice, 2023, 27(15): 104-107. DOI: 10.7619/jcmp.20231728 |
To investigate the inhibitory effect of tannic acid and different ratios of cefoperazone sodium to sulbactam sodium on carbapenem-resistant Acinetobacter baumannii (CRAB).
The minimum inhibitory concentrations (MICs) of tannic acid, the ratio of 1∶ 1 for cefoperazone sodium/sulbactam sodium and the ratio of 2∶ 1 for cefoperazone sodium/sulbactam sodium against six strains of CRAB were determined by micro-broth dilution method; the MIC of tannic acid combined with cefoperazone sodium-to-sulbactam sodium ratio against CRAB was determined by checkerboard dilution method, and the partial inhibitory concentration index (FICI) was calculated.
The MIC of tannic acid for the six strains of CRAB ranged from 128 μg/mL to 256 μg/mL; the MIC of cefoperazone sodium-to-sulbactam sodium ratio(1∶ 1) for six strains of CRAB ranged from 32 μg/mL to 128 μg/mL; the MIC of cefoperazone sodium-to-sulbactam sodium ratio(2∶ 1) for six strains of CRAB ranged from 64 μg/mL to 256 μg/mL; the FICI of tannic acid combined with cefoperazone sodium-to-sulbactam sodium(1∶ 1) was ranged from 0.375 to 0.750, showing synergistic and additive effects.
Cefoperazone sodium-to-sulbactam sodium ratio(1∶ 1) is more effective in bacterial inhibition for CRAB than cefoperazone sodium-to-sulbactam sodium ratio(2∶ 1). The combination of tannic acid and cefoperazone sodium-to-sulbactam sodium(1∶ 1) shows synergistic and additive effects and is expected to be a plane of the combination of Chinese and western drugs against CRAB.
[1] |
胡付品, 郭燕, 朱德妹, 等. 2021年CHINET中国细菌耐药监测[J]. 中国感染与化疗杂志, 2022, 22(5): 521-530. https://www.cnki.com.cn/Article/CJFDTOTAL-KGHL202205001.htm
|
[2] |
肖园园, 谭彩霞, 李春辉, 等. 美国感染病学会关于产超广谱β-内酰胺酶肠杆菌目细菌(ESBL-E)、耐碳青霉烯类肠杆菌目细菌(CRE)、难治性耐药铜绿假单胞菌(DTR-PA)、产AmpCβ-内酰胺酶肠杆菌目细菌(AmpC-E)、耐碳青霉烯类鲍曼不动杆菌(CRAB)和嗜麦芽窄食单胞菌的抗感染治疗指引(2022版)摘要[J]. 中国感染控制杂志, 2022, 21(12): 1267-1276. https://www.cnki.com.cn/Article/CJFDTOTAL-GRKZ202212018.htm
|
[3] |
徐令清, 杜良琴, 袁润奇, 等. 苏木及其活性成分对耐碳青霉烯类鲍曼不动杆菌的体外抑制作用研究[J]. 重庆医学, 2023, 52(5): 662-666, 671. https://www.cnki.com.cn/Article/CJFDTOTAL-CQYX202305005.htm
|
[4] |
尉骁, 侯渊博, 周铁丽, 等. 单宁酸对临床菌株的抗菌活性及其对生物膜的影响[J]. 温州医科大学学报, 2015, 45(10): 709-712. https://www.cnki.com.cn/Article/CJFDTOTAL-WZYX201510002.htm
|
[5] |
周华, 周建英, 俞云松. 中国鲍曼不动杆菌感染诊治与防控专家共识解读[J]. 中国循证医学杂志, 2016, 16(1): 26-29. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ201601006.htm
|
[6] |
王博, 磨国鑫, 周光, 等. 鲍曼不动杆菌产碳青霉烯酶对舒巴坦联合碳青霉烯抗生素协同作用的影响[J]. 解放军医学院学报, 2021, 42(4): 438-443, 450. https://www.cnki.com.cn/Article/CJFDTOTAL-JYJX202104015.htm
|
[7] |
AYOBAMI O, WILLRICH N, HARDER T, et al. The incidence and prevalence of hospital-acquired (carbapenem-resistant) Acinetobacter baumannii in Europe, Eastern Mediterranean and Africa: a systematic review and meta-analysis[J]. Emerg Microbes Infect, 2019, 8(1): 1747-1759.
|
[8] |
高吟, 张立红, 张志斌, 等. 小柴胡汤及亚胺培南西司他丁对耐碳青霉烯类鲍曼不动杆菌的体外抑菌效果及生物膜清除作用的机制研究[J]. 实用临床医药杂志, 2022, 26(18): 72-77. doi: 10.7619/jcmp.20220063
|
[9] |
YU S N, KIM T, PARK S Y, et al. Predictors of acute kidney injury and 28-day mortality in carbapenem-resistant Acinetobacter baumannii complex bacteremia[J]. Microb Drug Resist, 2021, 27(8): 1029-1036.
|
[10] |
MOHAPATRA S S, DWIBEDY S K, PADHY I. Polymyxins, the last-resort antibiotics: mode of action, resistance emergence, and potential solutions[J]. J Biosci, 2021, 46(3): 85.
|
[11] |
KENGKLA K, KONGPAKWATTANA K, SAOKAEW S, et al. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis[J]. J Antimicrob Chemother, 2018, 73(1): 22-32.
|
[12] |
MOHD SAZLLY LIM S, SIME F B, ROBERTS J A. Multidrug-resistant Acinetobacter baumannii infections: current evidence on treatment options and the role of pharmacokinetics/pharmacodynamics in dose optimisation[J]. Int J Antimicrob Agents, 2019, 53(6): 726-745.
|
[13] |
LAI C C, CHEN C C, LU Y C, et al. In vitro activity of cefoperazone and cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa[J]. Infect Drug Resist, 2019, 12: 25-29.
|
[14] |
祖瑞铃. 二氢丹参酮Ⅰ联合氨苄西林对表皮葡萄球菌生物膜形成及耐药逆转的作用研究[D]. 成都: 成都中医药大学, 2017.
|